In the clinical trial website, more than two FMD‐related clinical trials have been approved, including NCT04292041 for prostate cancer, NCT03700437 for non‐small cell lung cancer, NCT05384444 for colorectal cancer, NCT02126449 for human epidermal growth factor receptor 2‐negative breast cancer, NCT04248998 for triple‐negative breast cancer, and NCT05921149 for ovarian cancer. Here, ERBB2 is linked to lung cancer.